This study was designed to evaluate the prevalence of antifungal resistance, genetic mechanisms associated with in vitro induction of azole and echinocandin resistance and genotyping of Candida krusei, which is intrinsically resistant to fluconazole and is recovered from clinical and nonclinical sources from different countries. Our results indicated that all the isolates were susceptible or had the wild phenotype (WT) to azoles, amphotericin B, and only 1.27% showed non-WT for flucytosine. Although 70.88% of the isolates were resistant to caspofungin, none of them were categorized as echinocandin-resistant as all were susceptible to micafungin and no FKS1 hot spot 1 (HS1) or HS2 mutations were detected. In vitro induction of azole and echinocandin resistance confirmed the rapid development of resistance at low concentrations of fluconazole (4 μg/ml), voriconazole (0.06 μg/ml), and micafungin (0.03 μg/ml), with no difference between clinical and nonclinical isolates in the resistance development. Overexpression of ABC1 gene and FKS1 HS1 mutations were the major mechanisms responsible for azole and echinocandin resistance, respectively. Genotyping of our 79 isolates coupled with 217 other isolates from different sources and geography confirmed that the isolates belong to two main subpopulations, with isolates from human clinical material and Asia being more predominant in cluster 1, and environmental and animals isolates and those from Europe in cluster 2. Our results are of critical concern, since realizing that the C. krusei resistance mechanisms and their genotyping are crucial for guiding specific therapy and for exploring the potential infection source.

Antimicrobial Resistance Research Center National Institute of Infectious Diseases Tokyo Japan

Department of Botany Faculty of Science Charles University Prague Czech Republic

Department of Fungal Infection National Institute of Infectious Diseases Tokyo Japan

Department of Pharmacology Faculty of Veterinary Medicine Kafrelsheikh University Kafr El Sheikh Egypt

Division of Bio resources Medical Mycology Research Center Chiba University Chiba Japan

Division of Clinical Research Medical Mycology Research Center Chiba University Chiba Japan

Laboratory of Fungal Genetics and Metabolism Institute of Microbiology Czech Academy of Sciences Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22010990

003      

CZ-PrNML

005      

20220506130457.0

007      

ta

008      

220425s2022 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1128/AAC.01856-21 $2 doi

035    __

$a (PubMed)34871096

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Khalifa, Hazim O $u Division of Clinical Research, Medical Mycology Research Center, Chiba University, Chiba, Japan $u Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafr El-Sheikh, Egypt $1 https://orcid.org/0000000198619693

245    10

$a Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection / $c HO. Khalifa, V. Hubka, A. Watanabe, M. Nagi, Y. Miyazaki, T. Yaguchi, K. Kamei

520    9_

$a This study was designed to evaluate the prevalence of antifungal resistance, genetic mechanisms associated with in vitro induction of azole and echinocandin resistance and genotyping of Candida krusei, which is intrinsically resistant to fluconazole and is recovered from clinical and nonclinical sources from different countries. Our results indicated that all the isolates were susceptible or had the wild phenotype (WT) to azoles, amphotericin B, and only 1.27% showed non-WT for flucytosine. Although 70.88% of the isolates were resistant to caspofungin, none of them were categorized as echinocandin-resistant as all were susceptible to micafungin and no FKS1 hot spot 1 (HS1) or HS2 mutations were detected. In vitro induction of azole and echinocandin resistance confirmed the rapid development of resistance at low concentrations of fluconazole (4 μg/ml), voriconazole (0.06 μg/ml), and micafungin (0.03 μg/ml), with no difference between clinical and nonclinical isolates in the resistance development. Overexpression of ABC1 gene and FKS1 HS1 mutations were the major mechanisms responsible for azole and echinocandin resistance, respectively. Genotyping of our 79 isolates coupled with 217 other isolates from different sources and geography confirmed that the isolates belong to two main subpopulations, with isolates from human clinical material and Asia being more predominant in cluster 1, and environmental and animals isolates and those from Europe in cluster 2. Our results are of critical concern, since realizing that the C. krusei resistance mechanisms and their genotyping are crucial for guiding specific therapy and for exploring the potential infection source.

650    _2

$a zvířata $7 D000818

650    _2

$a antifungální látky $x farmakologie $x terapeutické užití $7 D000935

650    12

$a azoly $x farmakologie $7 D001393

650    _2

$a fungální léková rezistence $x genetika $7 D025141

650    12

$a echinokandiny $x farmakologie $7 D054714

650    _2

$a genotyp $7 D005838

650    _2

$a mikrobiální testy citlivosti $7 D008826

650    _2

$a Pichia $7 D010843

650    _2

$a prevalence $7 D015995

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Hubka, Vit $u Department of Botany, Faculty of Science, Charles University, Prague, Czech Republic $u Laboratory of Fungal Genetics and Metabolism, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic $u Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, Japan $1 https://orcid.org/0000000345836496 $7 mzk2016904736

700    1_

$a Watanabe, Akira $u Division of Clinical Research, Medical Mycology Research Center, Chiba University, Chiba, Japan $1 https://orcid.org/0000000230572937

700    1_

$a Nagi, Minoru $u Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan $u Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan

700    1_

$a Miyazaki, Yoshitsugu $u Department of Fungal Infection, National Institute of Infectious Diseases, Tokyo, Japan $1 https://orcid.org/0000000189420869

700    1_

$a Yaguchi, Takashi $u Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, Japan

700    1_

$a Kamei, Katsuhiko $u Division of Clinical Research, Medical Mycology Research Center, Chiba University, Chiba, Japan

773    0_

$w MED00009215 $t Antimicrobial agents and chemotherapy $x 1098-6596 $g Roč. 66, č. 2 (2022), s. e0185621

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34871096 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130450 $b ABA008

999    __

$a ok $b bmc $g 1788882 $s 1162188

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 66 $c 2 $d e0185621 $e 20211206 $i 1098-6596 $m Antimicrobial agents and chemotherapy $n Antimicrob Agents Chemother $x MED00009215

LZP    __

$a Pubmed-20220425